Distinction of High-Grade Neuroendocrine Carcinoma/Small Cell Carcinoma From Conventional Urothelial Carcinoma of Urinary Bladder

Thompson, Sherry; Cioffi-Lavina, Maureen; Chapman-Fredricks, Jennifer R.; Gomez‐Fernandez, Carmen; Fernandez-Castro, Gustavo; Jordà, Mercè

doi:10.1097/pai.0b013e31820eca9a

Cited by 22 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Es Das kleinzellige Karzinom der Harnblase, welches grundsätzlich anders therapiert wird, sollte mittels immunhistochemischer neuroendokriner Marker bestätigt werden. Da auch konventionelle Urothelkarzinome einen neuroendokrinen Immunphänotyp zeigen können, das Ansprechen auf eine neoadjuvante Chemotherapie für diese Tumoren aber unklar ist, sollten nur bei konventionell-morphologischem Bild eines kleinzelligen Karzinoms die immunhistochemischen Zusatzuntersuchungen erfolgen [70].…”

Section: Molekulare Biomarker In Der Urinzytologie Und Liquid-biopsy-diagnostikunclassified

Molekularpathologie bei urologischen Tumoren

et al. 2021

View full text Add to dashboard Cite

ZusammenfassungDas zunehmende Verständnis molekularer Grundlagen von Tumoren sowie der Fortschritt in der Diversifizierung der onkologischen Therapien versprechen individualisierte Therapieoptionen, welche bislang jedoch nur ansatzweise in die Therapieplanung von urologischen Tumoren eingegangen sind. Daher hat die Internationale Gesellschaft für Urologische Pathologie (ISUP) im März 2019 eine Konsenskonferenz zur Erarbeitung evidenzbasierter Handlungsempfehlungen zur molekularpathologischen Diagnostik beim Urothelkarzinom, Nierenzellkarzinom, Prostatakarzinom, Peniskarzinom und testikulären Keimzelltumoren durchgeführt. Die auf dieser Konsenskonferenz erarbeiteten Empfehlungen sind kürzlich in 5 separaten Manuskripten veröffentlich worden und werden in der vorliegenden Arbeit zusammengefasst.Im Rahmen der Konferenzvorbereitung wurde eine umfassende Umfrage zur derzeitigen Praxis molekularer Testungen bei urogenitalen Tumoren unter den Mitgliedern der ISUP durchgeführt. Auf der Konferenz wurden die Ergebnisse und die entsprechenden Hintergrundinformationen durch 5 Arbeitsgruppen präsentiert und Handlungsempfehlungen für die Diagnostik erarbeitet. Eine Übereinstimmung von 66 % der Konferenzteilnehmer wurde als Konsens definiert.

show abstract

Section: Molekulare Biomarker In Der Urinzytologie Und Liquid-biopsy-diagnostikunclassified

Molekularpathologie bei urologischen Tumoren

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Small cell bladder cancers have mutations in RB1, TP53, and the TERT promoter in the large majority of cases, though these alterations alone appear insufficient for small cell transformation (126). This variant expresses neuroendocrine markers, including synaptophysin, chromogranin, and CD56, and lacks expression of conventional UC markers, including high-molecular weight keratins and p63 (129). CD56 is the most sensitive marker (>90% sensitive) but the least specific, while synaptophysin and chromogranin are the more specific but less sensitive (70% sensitive) (130).…”

Section: Histologic Variants -Molecular Associations and Diagnostic Cmentioning

confidence: 99%

“…This may prove to be a useful marker in small cell carcinoma of the bladder, though it has not been reported to our knowledge. A subset of urothelial carcinomas have "small cell histology," but these express typical UC markers and lack expression of neuroendocrine markers (129). The ISUP WG recommends to confirm the morphological diagnosis of small cell carcinoma with immunohistochemistry to exclude this mimic.…”

Section: Histologic Variants -Molecular Associations and Diagnostic Cmentioning

confidence: 99%

Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer

Warrick

Knowles

Allory

et al. 2020

American Journal of Surgical Pathology

View full text Add to dashboard Cite

During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of molecular pathology, incorporating a premeeting survey. Bladder cancers are biologically diverse and can be separated into “molecular subtypes,” based on expression profiling. These subtypes associate with clinical behavior, histology, and molecular alterations, though their clinical utility has not been demonstrated at present and use in bladder cancer is not recommended. Mutations in the TERT promoter are present in the majority of bladder cancers, including the noninvasive stage of tumor evolution, but not in reactive conditions. Mutational analysis of the TERT promoter thus distinguishes histologically deceptive cancers from their benign mimics in some cases. A minority of pathologists employ this test. FGFR3 mutations are common in bladder cancer, and metastatic urothelial carcinoma (UC) with such mutations frequently responds to erdafitinib, an FGFR inhibitor. Testing for FGFR3 alterations is required before using this drug. Metastatic UC responds to immune-oncology (IO) agents in 20% of cases. These are approved as first and second-line treatments in metastatic UC. Several biological parameters associate with response to IO agents, including tumor mutational burden, molecular subtype, and infiltration by programmed death-ligand 1–positive lymphocytes, detected by immunohistochemistry. Programmed death-ligand 1 immunohistochemistry is mandatory before administering IO agents in the first-line setting. In conclusion, much has been learned about the biology of bladder cancer, and this understanding has improved the care of patients with the disease.

show abstract

“…TTF-1 может быть положительным примерно в 40 % наблюдений. SCNEC мочевого пузыря также может экспрессировать c-kit и EGFRоколо 30 % случаев [30,31]. В отличие от уротелиального рака SCNEC не экспрессирует такие органоспецифичные маркеры, как тромбомодулин, уроплакин III и высокомолекулярные цитокератины (34bE12, CK5 / 6) [32].…”

Section: нейроэндокринная карцинома почкиunclassified

Neuroendocrine tumors of the urinary system: literature review

et al. 2019

View full text Add to dashboard Cite

Most often, neuroendocrine carcinoma (NEC) is found in the gastrointestinal tract, broncho-pulmonary system, but they can also occur in other organs, such as the kidney, bladder, which is of most interest because of the rarity of this pathology. Until recently, there was not even a proper morphological classification for kidney NEC, and among some histological types, such as large cell neuroendocrine carcinoma of the kidney, only about 7 cases were recorded, and independent bladder carcinoids, about 15 cases. Currently, there are no clinical and morphological features of the NEC of the kidney and bladder, fundamentally distinguishing them from other neuroendocrine tumors and “classic” cancer of the same localization. This article also provides the data of the N.N. Blokhin National Medical Research Centre of Oncology on the incidence of all malignant neoplasms of the urinary system.

show abstract

Distinction of High-Grade Neuroendocrine Carcinoma/Small Cell Carcinoma From Conventional Urothelial Carcinoma of Urinary Bladder

Abstract: A limited immunohistochemical panel including pan-cytokeratin, synaptophysin, and p63 discriminates HGNEC/SmCC from high-grade UC.

Cited by 22 publications

References 0 publications

Molekularpathologie bei urologischen Tumoren

Molekularpathologie bei urologischen Tumoren

Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer

Neuroendocrine tumors of the urinary system: literature review

Contact Info

Product

Resources

About